RT @FlagshipPioneer: From pipeline developments and clinical milestones to new partnerships, hear from the CEOs and leaders of #FlagshipFou…

Our CEO, Michelle Werner, was in the @FlagshipPioneer Studio during #JPM25 to discuss groundbreaking progress in 2024, including advancing Alltrna’s first drug candidate to IND-enabling studies, and bold plans for 2025. From first-of-its-kind in vivo data of an engineered #tRNA medicine in rare liver disease models to innovative clinical strategies, Alltrna is redefining what’s possible in rare disease drug development. At Alltrna, we’re not just shaping the future of tRNA medicine—we’re shaping the future of medicine itself. Watch below or here: #JPM2025 #JPMHC25 #FlagshipJPM #FlagshipFounded #JPMWeek #BioWeekSF #StopCodonDisease

At Alltrna, we’re harnessing the power of #polyintelligence combining human ingenuity, nature’s adaptive brilliance, and machine precision—to unlock the potential of #tRNA therapeutics. Read more about this modern-day renaissance to decode nature and serve up solutions to allow humans to thrive in @NoubarAfeyan’s annual letter for @FlagshipPioneer: #JPM25 #FlagshipJPM #FlagshipFounded #AI

New year, new website! Alltrna’s expanded site dives deeper into our #tRNA platform, pipeline, and commitment to tackling #StopCodonDisease. Don’t miss the new educational materials and animation – a great way to learn about this groundbreaking science. Check it out and let us know what you think: #tRNA #RNA #tRNAmedicines #tRNAbiology #rarediseases #machinelearning #AI

We are excited to announce the appointment of Dr. Nerissa Kreher as Chief Medical Officer at Alltrna! Nerissa brings decades of expertise in rare disease drug development, with a proven track record of advancing innovative therapies and navigating complex regulatory pathways. Her leadership comes at a pivotal moment as we advance our first tRNA medicines to the clinic for liver Stop Codon Disease. Welcome to the team, Nerissa! Learn more: #tRNA #RNA #tRNAmedicines #tRNAbiology #rarediseases #raredisease #StopCodonDisease #geneticmedicines #PKU #Phenylketonuria #MMA #MethylmalonicAcidemia

As we say goodbye to 2024 and look to 2025, we reflect on a year of incredible progress, milestones, and momentum at Alltrna. Together, we’ve pushed the boundaries of #tRNA therapeutics, driven by our vision to build a better future for patients. #StopCodonDisease #WeAreAlltrna #BiggerLeaps #FlagshipFounded

The Alltrna team spread some holiday cheer with a festive cookie swap! From classic sugar cookies to creative new bakes, our team brought their A-game (and their aprons) to share the sweetness of the season. A big thank you to everyone who participated – and wishing everyone a joyful and delicious holiday season! 🍪🎁✨

Science isn’t just serious business at Alltrna—it’s fun, too! Meet Jalyce, a molecular biologist who loves diving into #tRNA complexity and being part of such an engaged, motivated team. 🎥 Watch the full video to learn about her journey and what excites her most about being part of Alltrna (SPOILER: some of it involves cats 😺) #WeAreAlltrna #lablife #tRNAbiology #EmployeeSpotlight #tRNAmedicines

Without tRNAs, we wouldn’t have proteins that carry out the functions of life. And when mutations like premature termination codons prevent a tRNA from carrying out its intended assignment, the resulting proteins might be incomplete and/or unable to function properly. Alltrna is developing medicines to rescue such proteins and restore function. In this informative interview with @DavidWild77 for the In Vivo Podcast, Alltrna CEO Michelle Werner explains how engineered tRNAs could transform the treatment landscape for rare diseases, and the company's journey to the clinic. Listen here: #InVivo #podcast #WomenInBiopharma #tRNAmedicines #tRNA #rarediseases #raredisease #StopCodonDisease #geneticmedicines #programmablemedicines #AI #machinelearning

We are excited to share that Shiva Krupa, Ph.D., has joined the Alltrna team as VP, Head of Program Management! With deep expertise in program and portfolio strategy, Shiva is poised to drive our programs from discovery through clinical development. Her extensive background includes leadership roles at Orna Therapeutics, AskBio, and Homology Medicines, where she advanced gene therapy programs across diverse therapeutic areas such as neuromuscular, cardiovascular, and oncology indications. Join us in welcoming Shiva to Alltrna! #tRNAmedicines #tRNA #rarediseases #raredisease #StopCodonDisease #geneticmedicines

🌟 Congratulations to our CEO, Michelle Werner, for being named one of 𝟮𝟬𝟮𝟰’s #𝗙𝗶𝗲𝗿𝗰𝗲𝟱𝟬 by @FierceHealth and Fierce Life Sciences! 🌟 At Alltrna, under Michelle’s leadership, we are pioneering a bold approach using engineered tRNA to restore protein function, with the potential to unify the treatment of genetic diseases with the same mutation. It is this kind of visionary science, coupled with Michelle’s steadfast commitment to the rare disease community, that drives us to push boundaries and build a new future for patients. Read more here: #tRNAmedicines #tRNA #rarediseases #raredisease #StopCodonDisease #geneticmedicines

We are pleased to announce the presentation of the first preclinical data on AP003, our lead development candidate. The engineered tRNA from this drug candidate showed clinically meaningful protein restoration in Stop Codon Disease models of methylmalonic acidemia (MMA) and phenylketonuria (PKU). These data support the potential for a basket approach to developing AP003 to treat genetic liver diseases caused by an Arg-TGA premature termination codon. See the press release for more info: #NatureConferences #tRNAmedicines #tRNA #rarediseases #raredisease #StopCodonDisease #geneticmedicines

Are recent advancements in drug development bringing us closer to new medicines for thousands of rare diseases where there currently are no treatments? Alltrna CEO Michelle Werner will join this @SciMagWebinars with other industry leaders to discuss how technology -- and the work of patients and advocates themselves -- are pushing the field forward. 𝗕𝗿𝗶𝗴𝗵𝘁 𝗯𝗿𝗲𝗮𝗸𝘁𝗵𝗿𝗼𝘂𝗴𝗵𝘀: 𝗥𝗲𝗮𝗹 𝘀𝘁𝗼𝗿𝗶𝗲𝘀 𝗼𝗳 𝗯𝗲𝗮𝘁𝗶𝗻𝗴 𝗿𝗮𝗿𝗲 𝗱𝗶𝘀𝗲𝗮𝘀𝗲 📆 Thursday, December 12, 2024 ⏰ 9am PT / 12pm ET / 5pm GMT / 6pm CET 🔗 #tRNAmedicines #tRNA #rarediseases #StopCodonDisease #geneticmedicines #patientpower

Alltrna’s CSO Chris Henderson will be presenting at RNA at the Bench and Bedside IV hosted by @NatureConf taking place December 9-11 at The Salk Institute in La Jolla, California. This event brings together research leaders to explore the latest advancements in translating RNA and tRNA biology into innovative therapies. We are excited to share more about how Alltrna is developing tRNA medicines to treat Stop Codon Disease. For more info on the conference, visit: #NatureConferences #tRNAmedicines #tRNA #rarediseases #raredisease #StopCodonDisease #geneticmedicines

As we work together to transform medicine, we never forget the power of teamwork, trust, and collaboration. This November, we dedicated an entire month to gratitude—celebrating our incredible team with meaningful moments of appreciation. From Thankful Thursdays featuring a potluck lunch to Thank You cards where we share personal notes of gratitude, we honored what makes Alltrna so special: our united spirit and relentless commitment to patients. #GratitudeMonth #TeamAlltrna #WeAreAlltrna #Gratitude

We are looking forward to the @Piper_Sandler 36th Annual Healthcare Conference taking place December 3-5 in New York City. Our CEO Michelle Werner will be presenting on how we are leveraging the Alltrna platform, enabled by AI and machine learning, to decipher tRNA biology and pioneer tRNA therapeutics to treat thousands of diseases. Learn more: #tRNAmedicines #tRNA #rarediseases #raredisease #StopCodonDisease #geneticmedicines

As leaders in translating tRNA biology into transformative medicines, we're proud to sponsor and present at the 𝟮𝟵𝘁𝗵 𝘁𝗥𝗡𝗔 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 in Kanazawa, Japan, from November 18-22. Since 1969, this biennial gathering has brought together experts to explore cutting-edge advancements in tRNA biology. We look forward to sharing Alltrna’s innovative approach in designing and delivering tRNA as a groundbreaking therapeutic modality. We will have a seminar and a poster where we will present proof-of-concept data on the ability of our engineered tRNAs to readthrough premature termination codons and restore protein production. We are excited about what these data mean for the potential creation of universal medicines to treat diseases that share these genetic mutations, collectively referred to as Stop Codon Disease. To see more about the conference, visit: #tRNAmedicines #tRNA #rarediseases #raredisease #StopCodonDisease #geneticmedicines #AI #machinelearning

Our CEO Michelle Werner will be participating in @Jefferies London Healthcare Conference 2024, and sharing how Alltrna is advancing universal tRNA medicines to restore disrupted protein production, regardless of target, for thousands of diseases with the same underlying genetic mutation. #JefferiesHealthcare #tRNAmedicines #tRNA #rarediseases #raredisease #StopCodonDisease #geneticmedicines

We are thrilled to welcome Sandra Visser, Ph.D., to the Alltrna team as SVP, Head of Therapeutics Development! With over two decades of experience in quantitative medicine, drug discovery, and strategic development, Sandra is driven by a passion for accelerating novel therapies and improving patient outcomes. Her impressive background includes leadership roles at GSK, Merck, and AstraZeneca, where she and her teams made groundbreaking advancements in preclinical and clinical drug projects. Join us in welcoming Sandra to Alltrna! #tRNAmedicines #tRNA #rarediseases #raredisease #StopCodonDisease #geneticmedicines